Comparative Pharmacology
Head-to-head clinical analysis: MPI DMSA KIDNEY REAGENT versus SODIUM POLYPHOSPHATE TIN KIT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MPI DMSA KIDNEY REAGENT versus SODIUM POLYPHOSPHATE TIN KIT.
MPI DMSA KIDNEY REAGENT vs SODIUM POLYPHOSPHATE-TIN KIT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
DMSA (dimercaptosuccinic acid) labeled with technetium-99m binds to renal cortex, particularly proximal tubular cells, allowing scintigraphic imaging of functional renal parenchyma. Uptake correlates with renal blood flow and tubular function.
Sodium polyphosphate-tin kit is used for radiolabeling with technetium-99m to form Tc-99m tin colloid, which is taken up by the reticuloendothelial system (liver, spleen, bone marrow) via phagocytosis. The mechanism of action for imaging involves targeting the mononuclear phagocytic system.
Adults: 74-185 MBq (2-5 mCi) intravenously, single dose for renal imaging.
Administer intravenously as a single dose of 5-10 mCi (185-370 MBq) of technetium-99m pertechnetate combined with the kit contents, after reconstitution and labeling per manufacturer instructions.
None Documented
None Documented
Initial whole-body half-life of dimer captosuccinic acid (DMSA) is 1.1 hours; terminal elimination half-life for cortical retention is 56 days, reflecting prolonged renal tubular uptake.
Terminal half-life of technetium-99m pertechnetate: 6 hours (physical decay). Biological half-life of polyphosphate variable; bone-bound activity persists for days.
Renal: ~50% excreted unchanged in urine within 24 hours; remaining fraction retained in renal tubular cells with gradual release over weeks.
Renal elimination of technetium-99m pertechnetate and polyphosphate. Approximately 30% excreted in urine within 24 hours; remainder cleared via bone uptake and slow release. Fecal excretion negligible.
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical